BioCentury
ARTICLE | Clinical News

Formation starts Phase I/IIa of AVID100 in solid tumors

May 18, 2017 6:39 PM UTC

Formation Biologics Inc. (Austin, Texas) began an open-label, U.S. Phase I/IIa trial of AVID100 in about 80 patients with advanced EGFR-positive solid tumors. Patients will receive escalating doses of IV AVID100 every 3 weeks in the Phase I portion to determine the recommended dose for the Phase IIa portion. The trial is evaluating safety as well as pharmacokinetics, the number of patients with an objective response or stable disease, and duration of response...

BCIQ Company Profiles

Forbius